Precision Radiotherapy on the Rise: Helical Tomotherapy Market Set to Surge from USD 169 Million to USD 408 Million by 2032
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Helical Tomotherapy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Helical Tomotherapy market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6074335/helical-tomotherapy
Market Analysis: Accelerating Growth in High-Precision Cancer Treatment
According to the latest market analysis, the global Helical Tomotherapy market was valued at approximately USD 169 million in 2025 and is projected to reach USD 408 million by 2032, growing at an exceptional compound annual growth rate (CAGR) of 13.6% from 2026 to 2032. This remarkable market growth – significantly outpacing the broader radiation oncology equipment market – reflects the increasing clinical adoption of helical tomotherapy as a preferred modality for complex cancer cases requiring extreme precision, including tumors adjacent to critical organs such as the brainstem, spinal cord, and optic nerves.
For hospital administrators, radiation oncology department heads, and healthcare investors, this market research signals a strong growth trajectory driven by technological superiority, expanding cancer incidence, and the ongoing shift from conventional radiotherapy toward image-guided, intensity-modulated approaches.
Product Definition: The Convergence of IGRT and IMRT in a Single Platform
Helical Tomotherapy (TOMO) is a high-precision radiotherapy technology that uniquely combines image-guided radiotherapy (IGRT) with intensity-modulated radiotherapy (IMRT) in an integrated system. Its core feature is the use of spiral CT scanning – analogous to diagnostic CT but adapted for therapeutic delivery – to dynamically irradiate the tumor from 360 degrees around the patient. This approach achieves high-dose target coverage with steep dose gradients, maximally protecting surrounding normal tissues and critical structures.
Unlike conventional linear accelerators (linacs) that deliver radiation from fixed gantry angles, helical tomotherapy’s rotating, fan-beam delivery enables dose painting – the ability to deliver different radiation doses to different sub-volumes within a single tumor. This capability is particularly valuable for treating irregularly shaped tumors or those with heterogeneous radioresistance.
The system operates through a ring gantry design, similar to a CT scanner, with a linear accelerator mounted on the rotating ring. As the gantry rotates, the treatment couch moves continuously through the bore, creating a helical treatment path. A binary multileaf collimator modulates the beam in real time, turning the beam on and off up to 51 times per rotation to sculpt the dose distribution precisely to the tumor volume.
Key Industry Trends Driving Market Expansion
Industry Trend 1: Growing Demand for Precision Radiotherapy in Complex Cases
The primary driver of helical tomotherapy adoption is the increasing complexity of cancer cases requiring treatment. According to the International Agency for Research on Cancer (IARC) Global Cancer Observatory data released in February 2025, global new cancer cases reached 20.8 million in 2024, with projections exceeding 22 million by 2030. Critically, the proportion of cases diagnosed at advanced stages or involving anatomically complex sites – head and neck, central nervous system, lung, and prostate cancers – has increased from approximately 35 percent in 2015 to 42 percent in 2024, driven by improved diagnostic imaging.
In these complex cases, the dosimetric advantages of helical tomotherapy over conventional IMRT are well-documented. A multi-center retrospective study published in the International Journal of Radiation Oncology, Biology, Physics (October 2024) comparing helical tomotherapy to fixed-field IMRT for paraspinal tumors found that tomotherapy reduced mean spinal cord dose by 28 percent (p<0.01) while maintaining equivalent target coverage. This translates directly to reduced risk of radiation myelitis – a devastating complication – and enables dose escalation for radioresistant tumors.
Industry Trend 2: Expansion of Tomotherapy Applications Beyond Conventional Indications
Beyond standard applications, helical tomotherapy is finding new utility in total marrow irradiation (TMI) and total lymphoid irradiation (TLI) for hematologic malignancies – indications where conventional linacs face technical limitations. At the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting (held March 2025 in Chicago), researchers from Memorial Sloan Kettering Cancer Center presented data on TMI using helical tomotherapy in 45 patients undergoing conditioning for allogeneic stem cell transplantation. The results showed excellent organ sparing (mean lung dose <8 Gy, mean renal dose <10 Gy) with no grade 3 or higher treatment-related toxicities – outcomes superior to historical conventional TMI series.
Furthermore, the integration of adaptive radiotherapy capabilities into newer tomotherapy platforms represents a significant industry trend. Adaptive radiotherapy – modifying the treatment plan based on daily anatomical changes – is particularly valuable for head and neck and cervical cancer patients where tumor shrinkage or weight loss alters target geometry during a six-to-seven-week treatment course. Accuray (which acquired TomoTherapy Inc. in 2011) has incorporated iterative cone-beam CT-based adaptive planning into its Radixact platform, with the first clinical outcomes presented at ESTRO 2025 (European Society for Radiotherapy and Oncology, held April 2025 in Vienna) demonstrating a 41 percent reduction in parotid gland dose compared to non-adaptive IMRT.
Industry Trend 3: Regional Disparities in Adoption and Reimbursement
The market share distribution for helical tomotherapy varies significantly by geography, reflecting differences in healthcare reimbursement policies and capital equipment budgeting cycles. North America currently accounts for approximately 45 percent of global market size, driven by favorable reimbursement through the Medicare Hospital Outpatient Prospective Payment System (HOPPS) where tomotherapy is reimbursed under the same ambulatory payment classification (APC) as linac-based IMRT – removing financial disincentives for adoption.
Europe follows with approximately 30 percent market share, led by Germany, France, and the United Kingdom. However, adoption in Southern and Eastern Europe remains constrained by capital budget limitations, with tomotherapy systems concentrated in major academic centers. The Asia-Pacific region represents the fastest-growing segment, with a projected CAGR of 15 to 17 percent through 2032, supported by China’s tiered healthcare infrastructure investments – including specific provincial subsidies for advanced radiotherapy equipment in the 14th Five-Year Plan (2021-2025, with carryover funding through 2026) – and India’s National Cancer Grid expansion.
Competitive Landscape: A Focused Duopoly with Clear Distinction
The helical tomotherapy market is uniquely concentrated, with only two primary participants identified in QYResearch’s segmentation:
Accuray Incorporated: Following its acquisition of TomoTherapy Inc. for USD 277 million in 2011, Accuray has been the primary commercializer of helical tomotherapy systems. The company’s current Radixact platform – cleared by the FDA in 2017 and updated with Synchrony motion synchronization technology in 2024 – represents the ninth generation of tomotherapy technology. According to Accuray’s fiscal year 2024 annual report (filed with the SEC in August 2024), the company has over 1,200 tomotherapy systems installed globally, generating approximately USD 240 million in product revenue and USD 110 million in service revenue annually. The company’s gross margin for product revenue is approximately 38 percent, with service margins exceeding 45 percent.
TomoTherapy (as a legacy brand): While TomoTherapy Inc. no longer exists as an independent entity, its earlier-generation Hi·Art systems remain in clinical operation at hundreds of sites worldwide. These systems – installed between 2003 and 2011 – continue to generate service and parts revenue for Accuray and authorized third-party service providers. However, no new Hi·Art systems have been manufactured since 2011, and the market share of legacy systems is declining as sites upgrade to Radixact or replace with competing technologies.
From an exclusive analyst perspective, the absence of direct competition from major linac manufacturers (Varian, Elekta, Siemens Healthineers) in the dedicated helical tomotherapy space is notable. These competitors offer IGRT/IMRT capabilities on conventional linacs but have not developed dedicated helical delivery platforms. This creates a competitive moat for Accuray in the niche where helical delivery’s dosimetric advantages are clinically compelling – particularly for multiple metastases (stereotactic body radiotherapy for oligometastatic disease) and craniospinal irradiation for pediatric medulloblastoma.
Market Segmentation and Application Breakdown
The Helical Tomotherapy market is segmented as follows:
Segment by Type:
Equipment: New system sales, including Radixact and remaining legacy Hi·Art systems. This segment accounts for approximately 60 to 65 percent of market size.
Therapeutic Solution: Service contracts, treatment planning software upgrades, and training. This recurring revenue segment is growing as a percentage of total revenue, consistent with the broader radiotherapy industry trend toward “razor and blade” business models.
Segment by Application:
Hospital: Tertiary referral centers and comprehensive cancer centers account for approximately 80 percent of installations, driven by high patient volumes and multi-disciplinary care teams.
Clinic: Freestanding radiation oncology centers account for approximately 15 percent, primarily in markets with favorable reimbursement (U.S., Germany).
Others: Academic research centers and veterinary oncology applications (an emerging niche) account for the remaining 5 percent.
Exclusive Analyst Insight: The Purchase vs. Service Revenue Dynamic
From my industry analysis perspective, a distinctive and often-overlooked feature of the helical tomotherapy market is the inverse relationship between equipment and service revenue growth. As installed base expands – projected to exceed 1,600 systems globally by 2032 – service and parts revenue will grow as a percentage of total market revenue, from approximately 35 percent in 2025 to an estimated 50 percent by 2030. This shift has important implications for investors: companies with large installed bases (i.e., Accuray) benefit from stable, high-margin recurring revenue even during periods of capital equipment purchasing pauses (e.g., hospital budget freezes).
For CEOs of radiation oncology providers, the strategic decision to invest in helical tomotherapy versus conventional linacs should be guided by case mix. For centers treating high volumes of complex cases (head and neck, CNS, total marrow irradiation), the dosimetric advantages and 13.6 percent market growth trajectory justify capital investment. For centers focused on conventional breast, prostate, or palliative cases, linac-based IMRT may remain cost-effective.
In conclusion, the helical tomotherapy market offers a compelling growth narrative driven by the convergence of rising cancer incidence, demand for precision radiotherapy, and unique technological differentiation. Its projected USD 408 million market size by 2032 – while relatively modest compared to the broader radiotherapy equipment market – represents a high-growth, high-margin niche with durable competitive advantages for the incumbent player.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
